[go: up one dir, main page]

TN2009000135A1 - Use of modified cyclosporins - Google Patents

Use of modified cyclosporins

Info

Publication number
TN2009000135A1
TN2009000135A1 TNP2009000135A TN2009000135A TN2009000135A1 TN 2009000135 A1 TN2009000135 A1 TN 2009000135A1 TN P2009000135 A TNP2009000135 A TN P2009000135A TN 2009000135 A TN2009000135 A TN 2009000135A TN 2009000135 A1 TN2009000135 A1 TN 2009000135A1
Authority
TN
Tunisia
Prior art keywords
cyclosporins
modified
modified cyclosporins
prevention
treatment
Prior art date
Application number
TNP2009000135A
Other languages
English (en)
Inventor
Motoyuki Kohjima
Makoto Nakamuta
Original Assignee
Univ Kyushu
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu, Novartis Ag filed Critical Univ Kyushu
Publication of TN2009000135A1 publication Critical patent/TN2009000135A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TNP2009000135A 2006-10-12 2009-04-10 Use of modified cyclosporins TN2009000135A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82922806P 2006-10-12 2006-10-12
PCT/EP2007/060794 WO2008043797A1 (fr) 2006-10-12 2007-10-10 Utilisation de cyclosporines modifiées

Publications (1)

Publication Number Publication Date
TN2009000135A1 true TN2009000135A1 (en) 2010-10-18

Family

ID=39092021

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000135A TN2009000135A1 (en) 2006-10-12 2009-04-10 Use of modified cyclosporins

Country Status (17)

Country Link
US (1) US20100130408A1 (fr)
EP (1) EP2073831A1 (fr)
JP (1) JP5455632B2 (fr)
KR (1) KR20090083902A (fr)
CN (1) CN101557819A (fr)
AU (1) AU2007306316B2 (fr)
BR (1) BRPI0719189A2 (fr)
CA (1) CA2665415A1 (fr)
IL (1) IL197966A0 (fr)
MA (1) MA30865B1 (fr)
MX (1) MX2009003743A (fr)
NO (1) NO20091694L (fr)
RU (1) RU2463071C2 (fr)
SG (1) SG175621A1 (fr)
TN (1) TN2009000135A1 (fr)
WO (1) WO2008043797A1 (fr)
ZA (1) ZA200902300B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN101843893B (zh) * 2010-05-21 2012-02-01 中国人民解放军第三军医大学 环孢素a在制备抗轮状病毒药物中的应用
EP3351247A1 (fr) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Inhibiteurs benzoquinolone de vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6542222B2 (ja) 2013-12-03 2019-07-10 オースペックス ファーマシューティカルズ インコーポレイテッド ベンゾキノリン化合物の製造方法
HK1249860A1 (zh) 2015-03-06 2018-11-16 奥斯拜客斯制药有限公司 用於治疗异常不自主运动障碍的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
JP4350898B2 (ja) * 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
ES2365692T3 (es) * 1999-04-27 2011-10-10 Mitsubishi Tanabe Pharma Corporation Medicamento para la prevención o tratamiento terapéutico de enfermedades hepáticas.
AU2001292301A1 (en) * 2000-10-11 2002-04-22 Daiichi Pharmaceutical Co., Ltd. Novel drugs for liver diseases
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7079552B2 (en) * 2003-09-09 2006-07-18 Harris Corporation Mobile ad hoc network (MANET) with quality-of-service (QoS) protocol hierarchy and related methods
EP1802650B1 (fr) * 2004-10-01 2011-10-26 Scynexis, Inc. Derives de cyclosporine 3-ether et 3-thioether substitues utilises dans le traitement et la prevention d'une infection par hepatite c
ES2357587T3 (es) * 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
WO2006071619A1 (fr) * 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors

Also Published As

Publication number Publication date
MX2009003743A (es) 2009-06-18
ZA200902300B (en) 2010-10-27
IL197966A0 (en) 2011-08-01
EP2073831A1 (fr) 2009-07-01
MA30865B1 (fr) 2009-11-02
WO2008043797A1 (fr) 2008-04-17
US20100130408A1 (en) 2010-05-27
KR20090083902A (ko) 2009-08-04
JP5455632B2 (ja) 2014-03-26
CA2665415A1 (fr) 2008-04-17
AU2007306316A1 (en) 2008-04-17
BRPI0719189A2 (pt) 2018-08-14
SG175621A1 (en) 2011-11-28
AU2007306316B2 (en) 2011-10-27
CN101557819A (zh) 2009-10-14
NO20091694L (no) 2009-07-10
RU2463071C2 (ru) 2012-10-10
JP2010505912A (ja) 2010-02-25
RU2009117699A (ru) 2010-11-20

Similar Documents

Publication Publication Date Title
TNSN07240A1 (en) Compounds for flaviviridae treatment
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TN2009000135A1 (en) Use of modified cyclosporins
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
GB201020032D0 (en) Composition
WO2008014200A3 (fr) Compositions de cyclosporine
WO2007001851A3 (fr) Préparations et méthodes pour le diagnostic et le traitement d'une tumeur
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX357801B (es) Agentes dirigidos a gadd45beta.
MX356129B (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
PT1854477T (pt) Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
MX2012009748A (es) USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.
MY160041A (en) Compositions and methods for treating parasitic infections
MX2010001779A (es) Peptidos para vacunas.
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MX2012006628A (es) Microorganismos probioticos como agentes activos para mejorar el brillo de la piel.
MY147247A (en) Organic compounds and their uses
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2010003045A (es) Composiciones de ciclosporina.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
WO2008078167A3 (fr) Peptide de consensus
WO2009132231A8 (fr) Peptidyl-diacylglycérides
MX2010005915A (es) Derivados de fenil-oxetanilo.